TACT Study by NIH on EDTA Chelation Therapy

EDTA Chelation Therapy Proves Highly Significant Benefits Up to 50% prevention of recurrent heart attacks and 43 percent reduction in death rate from all causes.


At the American Heart Association meeting in Los Angeles on November 4, 2012, Dr. Gervasio Lamas, principal investigator, presented results of the NIH-sponsored Trial to Assess Chelation Therapy (TACT). This randomized, placebo-controlled study of 1,708 patients showed  that intravenous disodium EDTA chelation therapy decreased subsequent cardiac events with statistical significance, when compared to a control group of similar patients who received placebo.

Cardiologists from prestigious medical schools joined a total of 134 medical centers across the U.S. and Canada who participated in this study, at a cost of $30 million. Statistical analysis showed benefits to be highly significant.

Cardiac events that were reduced included fewer deaths, fewer heart attacks, and fewer strokes, less need for cardiovascular surgery, and fewer hospitalizations for heart problems. Chelation therapy shown to be safe, without any serious side effects. Patients experienced increasing benefits during the time that they were studied?up to five years thus far.

In his presentation, he says: “I never believe in Chelation Therapy but the result surprised me, it’s time the wrong to be right”
Now sample being gathered for TACT2 with 100 multi-centres all over USA and Canada, to start in 2016.
Gervasio Lamas, MD, FACC, FAHA, FESC
  • Chairman of Medicine
  • Chief, Columbia University Division of Cardiology at Mount Sinai Medical Center
  • Professor of Medicine, Columbia University Medical Center
  • Co-Director, Mount Sinai Heart Institute